|
Today's Headlines
The first 2 drugs in a new class of cholesterol-lowering medications, called PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, are expected to be approved by FDA. If approved, they will be the first specialty drugs to treat a common chronic condition, high cholesterol, raising questions about how health plans, employers and members will afford the expected high price tag.
» Wait until you read this
|
|
Alcohol and drug addiction organizations praised the passage of a new Florida law that will increase access to naloxone, which immediately reverses the effects of opioids in the event of an overdose.
» How many lives has naloxone saved?
|
Continuing Education
This month’s CE activity is part of a CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month’s activity is to assist pharmacists in understanding the pathophysiology and pharmacologic treatment of COPD and to discuss how COPD is similar to and different from other chronic respiratory disorders.
To read and print the article with TEST questions, click here.
To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT31-KTJ28.
Announcement: The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. To review your registration page or to register, go to: https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
Ibrutinib may be a safe and potentially effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were refractory to steroid treatment or steroid-dependent, suggested interim data presented at ASCO. » Study details
|
|
|
Like
Tweet
